Go to the Globe and Mail homepage

Jump to main navigationJump to main content


Funds that bought in to Valeant – and lost Add to ...

Subscribers Only

The remarkable collapse of the shares of Valeant Pharmaceuticals International Inc. didn’t just harm investors who chose to buy directly into the stock. Because of its brief honour of being the most valuable company in the S&P/TSX 60, Valeant shares found their way into dozens of Canadian mutual and exchange-traded funds, in many cases taking up an ample proportion of the portfolio.

Report Typo/Error

Follow us on Twitter: @GlobeInvestor

Next story




Most popular videos »

More from The Globe and Mail

Most popular